| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2019 | Loonat AA, Martin ED, Sarafraz-Shekary N, Tilgner K, Hertz NT, Levin R, Shokat KM, Burlingame AL, Arabacilar P, Uddin S, Thomas M, Marber MS, Clark JE. p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701545R. PMID 31638431 DOI: 10.1096/Fj.201701545R | 0.762 | |||
| 2019 | Baark F, Shaughnessy F, Pell VR, Clark JE, Eykyn TR, Blower P, Southworth R. Tissue acidosis does not mediate the hypoxia selectivity of [Cu][Cu(ATSM)] in the isolated perfused rat heart. Scientific Reports. 9: 499. PMID 30679497 DOI: 10.1038/s41598-018-36145-1 | 0.688 | |||
| 2019 | Safee ZM, Baark F, Waters ECT, Veronese M, Pell VR, Clark JE, Mota F, Livieratos L, Eykyn TR, Blower PJ, Southworth R. Detection of anthracycline-induced cardiotoxicity using perfusion-corrected Tc sestamibi SPECT. Scientific Reports. 9: 216. PMID 30659226 DOI: 10.1038/s41598-018-36721-5 | 0.701 | |||
| 2018 | Pell VR, Baark F, Mota F, Clark JE, Southworth R. PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts. Current Cardiovascular Imaging Reports. 11: 7. PMID 29515752 DOI: 10.1007/s12410-018-9447-3 | 0.688 | |||
| 2017 | Aubdool AA, Thakore P, Argunhan F, Smillie SJ, Schnelle M, Srivastava S, Alawi KM, Wilde E, Mitchell J, Farrell-Dillon K, Richards DA, Maltese G, Siow RC, Nandi M, Clark JE, et al. A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy and Heart Failure. Circulation. PMID 28446517 DOI: 10.1161/Circulationaha.117.028388 | 0.312 | |||
| 2014 | Bodkin JV, Thakore P, Aubdool AA, Liang L, Fernandes ES, Nandi M, Spina D, Clark JE, Aaronson PI, Shattock MJ, Brain SD. Investigating the potential role of TRPA1 in locomotion and cardiovascular control during hypertension. Pharmacology Research & Perspectives. 2: e00052. PMID 25505598 DOI: 10.1002/prp2.52 | 0.537 | |||
| 2014 | Boguslavskyi A, Pavlovic D, Aughton K, Clark JE, Howie J, Fuller W, Shattock MJ. Cardiac hypertrophy in mice expressing unphosphorylatable phospholemman. Cardiovascular Research. 104: 72-82. PMID 25103111 DOI: 10.1093/cvr/cvu182 | 0.564 | |||
| 2014 | Samuelsson AM, Clark J, Rudyk O, Shattock MJ, Bae SE, South T, Pombo J, Redington K, Uppal E, Coen CW, Poston L, Taylor PD. Response to role of hyperleptinemia in the regulation of blood pressure and cardiac function. Hypertension. 63: e2. PMID 24475477 DOI: 10.1161/Hypertensionaha.113.02399 | 0.55 | |||
| 2013 | Dhanjal TS, Medina RA, Leem J, Clark JE, Southworth R, Curtis MJ. Trapped platelets activated in ischemia initiate ventricular fibrillation. Circulation. Arrhythmia and Electrophysiology. 6: 995-1001. PMID 23995251 DOI: 10.1161/CIRCEP.113.000591 | 0.745 | |||
| 2013 | Samuelsson AM, Clark J, Rudyk O, Shattock MJ, Bae SE, South T, Pombo J, Redington K, Uppal E, Coen CW, Poston L, Taylor PD. Experimental hyperleptinemia in neonatal rats leads to selective leptin responsiveness, hypertension, and altered myocardial function. Hypertension. 62: 627-33. PMID 23836797 DOI: 10.1161/Hypertensionaha.111.00691 | 0.529 | |||
| 2010 | Kumphune S, Bassi R, Jacquet S, Sicard P, Clark JE, Verma S, Avkiran M, O'Keefe SJ, Marber MS. A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580. The Journal of Biological Chemistry. 285: 2968-75. PMID 19996096 DOI: 10.1074/jbc.M109.079228 | 0.3 | |||
| 2009 | Breckenridge RA, Zuberi Z, Gomes J, Orford R, Dupays L, Felkin LE, Clark JE, Magee AI, Ehler E, Birks EJ, Barton PJ, Tinker A, Mohun TJ. Overexpression of the transcription factor Hand1 causes predisposition towards arrhythmia in mice. Journal of Molecular and Cellular Cardiology. 47: 133-41. PMID 19376125 DOI: 10.1016/j.yjmcc.2009.04.007 | 0.316 | |||
| 2009 | Gorog DA, Jabr RI, Tanno M, Sarafraz N, Clark JE, Fisher SG, Cao XB, Bellahcene M, Dighe K, Kabir AM, Quinlan RA, Kato K, Gaestel M, Marber MS, Heads RJ. MAPKAPK-2 modulates p38-MAPK localization and small heat shock protein phosphorylation but does not mediate the injury associated with p38-MAPK activation during myocardial ischemia. Cell Stress & Chaperones. 14: 477-89. PMID 19214782 DOI: 10.1007/s12192-009-0101-5 | 0.725 | |||
| 2009 | Clark JE, Kottam A, Motterlini R, Marber MS. Measuring left ventricular function in the normal, infarcted and CORM-3-preconditioned mouse heart using complex admittance-derived pressure volume loops. Journal of Pharmacological and Toxicological Methods. 59: 94-9. PMID 19059354 DOI: 10.1016/j.vascn.2008.10.007 | 0.587 | |||
| 2008 | Jacquet S, Nishino Y, Kumphune S, Sicard P, Clark JE, Kobayashi KS, Flavell RA, Eickhoff J, Cotten M, Marber MS. The role of RIP2 in p38 MAPK activation in the stressed heart. The Journal of Biological Chemistry. 283: 11964-71. PMID 18310079 DOI: 10.1074/Jbc.M707750200 | 0.348 | |||
| 2008 | Bassi R, Heads R, Marber MS, Clark JE. Targeting p38-MAPK in the ischaemic heart: kill or cure? Current Opinion in Pharmacology. 8: 141-6. PMID 18289939 DOI: 10.1016/j.coph.2008.01.002 | 0.355 | |||
| 2008 | Bell JR, Kennington E, Fuller W, Dighe K, Donoghue P, Clark JE, Jia LG, Tucker AL, Moorman JR, Marber MS, Eaton P, Dunn MJ, Shattock MJ. Characterization of the phospholemman knockout mouse heart: depressed left ventricular function with increased Na-K-ATPase activity. American Journal of Physiology. Heart and Circulatory Physiology. 294: H613-21. PMID 18065526 DOI: 10.1152/ajpheart.01332.2007 | 0.594 | |||
| 2007 | Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacology & Therapeutics. 116: 192-206. PMID 17765316 DOI: 10.1016/j.pharmthera.2007.06.013 | 0.729 | |||
| 2007 | Bell RM, Clark JE, Hearse DJ, Shattock MJ. Reperfusion kinase phosphorylation is essential but not sufficient in the mediation of pharmacological preconditioning: Characterisation in the bi-phasic profile of early and late protection. Cardiovascular Research. 73: 153-63. PMID 17126307 DOI: 10.1016/J.Cardiores.2006.10.013 | 0.64 | |||
| 2006 | Kabir AM, Clark JE, Tanno M, Cao X, Hothersall JS, Dashnyam S, Gorog DA, Bellahcene M, Shattock MJ, Marber MS. Cardioprotection initiated by reactive oxygen species is dependent on activation of PKCepsilon. American Journal of Physiology. Heart and Circulatory Physiology. 291: H1893-9. PMID 16714357 DOI: 10.1152/ajpheart.00798.2005 | 0.584 | |||
| 2004 | Foresti R, Hammad J, Clark JE, Johnson TR, Mann BE, Friebe A, Green CJ, Motterlini R. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. British Journal of Pharmacology. 142: 453-60. PMID 15148243 DOI: 10.1038/sj.bjp.0705825 | 0.636 | |||
| 2003 | Motterlini R, Mann BE, Johnson TR, Clark JE, Foresti R, Green CJ. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Current Pharmaceutical Design. 9: 2525-39. PMID 14529551 | 0.632 | |||
| 2003 | Johnson TR, Mann BE, Clark JE, Foresti R, Green CJ, Motterlini R. Metal carbonyls: a new class of pharmaceuticals? Angewandte Chemie (International Ed. in English). 42: 3722-9. PMID 12923835 DOI: 10.1016/S0162-0134(03)80662-1 | 0.633 | |||
| 2003 | Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, Foresti R, Motterlini R. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circulation Research. 93: e2-8. PMID 12842916 DOI: 10.1161/01.RES.0000084381.86567.08 | 0.702 | |||
| 2002 | Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circulation Research. 90: E17-24. PMID 11834719 | 0.648 | |||
| Show low-probability matches. | |||||